180863-55-2

Usage

Uses

Used in Food Industry:
Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-, methyl ester is used as a food preservative for its ability to inhibit the growth of bacteria and fungi, thereby extending the shelf life of various food products. Its sweet and slightly astringent taste also makes it a suitable flavoring agent in certain food items.
Used in Cosmetic and Personal Care Industry:
In the cosmetic and personal care sector, this chemical compound serves as a preservative to prevent microbial contamination, ensuring the safety and efficacy of products. Its antimicrobial properties help maintain product integrity and protect consumers from potential infections.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, given its antimicrobial properties, Benzoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-, methyl ester could potentially be utilized in the pharmaceutical industry for the preservation of medications and other health-related products, ensuring their stability and safety for consumption.

Upstream product

• 6515-58-8 3-bromomethylbenzoic acid 
• 99-04-7 m-Toluic acid 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 2905-65-9 methyl 3-chlorobenzoate 
• 1314538-55-0 potassium tert-butyl N-[(trifluorolambda-4-boranyl)methyl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 781632-38-0 3-(1, 3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-benzoic acid methyl ester 
• 13531-48-1 methyl 3-cyanobenzoate 
• 93071-65-9 3-methoxycarbonyl benzylamine 

Downstream Products

• 180863-35-8 3-[(tert-butoxycarbonyl-methyl-amino)-methyl]-benzoic acid methyl ester 
• 117445-22-4 3-(tert-butoxycarbonylamino-methyl)benzoic acid 
• 170853-04-0 t-butyl N-(3-formylbenzyl)carbamate 
• 226070-69-5 1,1-dimethylethyl {[3-(hydroxymethyl)phenyl]methyl}carbamate 
• 93071-65-9 3-methoxycarbonyl benzylamine 

Relevant academic research and scientific papers

HISTONE DEACETYLASE INHIBITORS

The disclosure provides compounds of formula I and methods for preparation thereof. The compounds act as inhibitor of histone deacetylase.

Synthesis and Suzuki-Miyaura cross-coupling reactions of potassium Boc-protected aminomethyltrifluoroborate with aryl and hetaryl halides

Potassium Boc-protected aminomethyltrifluoroborate, a primary aminomethyl equivalent, was synthesized successfully through a "one-pot" process. With this trifluoroborate, Suzuki-Miyaura cross-coupling reactions were investigated with a variety of both aryl and hetaryl chlorides in good to excellent yields.

HISTONE DEACETYLASE INHIBITORS

The disclosure provides compounds of formula I and methods for preparation thereof. The compounds act as inhibitor of histone deacetylase.

IMIDAZOLE CARBOXAMIDES

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

11beta-HSD1 Inhibitors

The invention relates to compounds of formula (I) wherein A, Y, Z1, Z2, R1 to R3 and X1 to X4 have the meaning as cited in the description and the claims. For example A is 4'-fluorobiphen-4-yl; Y is -S(O)2NH-; R1, R2 are H; X1, X2, X4 are CH; X3 is C-F; Z1 is =O; and Z2-R3 is N(CH2CH3)2. Said compounds are useful as 11β-HSD1 inhibitors. The invention also relates to the preparation of such compounds as well as the production and use as medicament.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Sulfonyl derivatives

Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1is hydrogen, hydroxyl, nitro or the like; R2and R3are each independently hydrogen, halogeno or the like; R4and R5are each dependently hydrogen, halogeno or the like; Q1is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2is a single bond, oxygen or the like; Q3is, e.g., a group represented by formula (a): T1is carbonyl or the like; and X1and X2are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

PRODRUGS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention comprises peptidomimetic compounds which comprise a suitably substituted aminoalkylbenzamide moiety. The instant compounds inhibit the farnesyl protein transferase enzyme and the farnesylation of certain proteins. Furthermore, the in